Latest posts
-
Lipella Pharmaceuticals Granted FDA Orphan Designation for Oral Graft-versus-Host Disease Drug
“GvHD affects approximately 30,000 Americans and oral GvHD causes significant oral pain and discomfort, making it difficult for patients to eat, drink and speak. Oral GvHD is a great unmet need in cancer survivors.” Dr. Michael Chancellor, Chief Medical Officer at Lipella Pharmaceuticals Pittsburgh, PA, November 10, 2023 – Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella,”
-
Lipella Pharmaceuticals to Present at the Fall Foliage MicroCap Rodeo Conference
Pittsburgh, PA, October 23, 2023 – Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella,” “our, “us” or the “Company”), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, will present at the 2023 virtual Fall Foliage MicroCap Rodeo Conference to be held from October 24th – 27th. Dr. Jonathan Kaufman, CEO of Lipella, said: “2023